Yahoo
    NasdaqGM - Nasdaq Real Time Price USD

    LB Pharmaceuticals Inc (LBRX)

    39.70 -0.45 (-1.12%)
    At close: October 30 at 4:00:01 PM EDT
    40.20 +0.50 (+1.26%)
    After hours: October 30 at 4:15:22 PM EDT
    Trade LBRX on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for LBRX
    Chart does not reflect overnight price.
    • Previous Close 40.15
    • Open 40.10
    • Bid 32.42 x 200
    • Ask 57.43 x 200
    • Day's Range 39.12 - 41.24
    • 52 Week Range 14.32 - 50.16
    • Volume 429,474
    • Avg. Volume 368,262
    • Market Cap (intraday) 1.281B
    • Beta (5Y Monthly) --
    • PE Ratio (TTM) 397.00
    • EPS (TTM) 0.10
    • Earnings Date (est.) Nov 12, 2026
    • Forward Dividend & Yield -- (0.00%)
    • 1y Target Est 58.00
    • Zacks Rating Bearish

    LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

    lbpharma.us

    49

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Biotechnology

    Industry

    More about LB Pharmaceuticals Inc

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

    YTD Return

    LBRX
    78.35%
    S&P 500 (^GSPC)
    10.73%

    1-Year Return

    LBRX
    143.86%
    S&P 500 (^GSPC)
    11.11%

    3-Year Return

    LBRX
    108.95%
    S&P 500 (^GSPC)
    81.91%

    5-Year Return

    LBRX
    108.95%
    S&P 500 (^GSPC)
    64.59%

    Earnings Trends

    View More

    Earnings Per Share

    GAAP
    Normalized
    GAAP
    Normalized

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q2 FY26
    Revenue --
    Earnings -51.6M
    Profit Margin 0.00%

    Q3

    FY25

    Q4

    FY25

    Q2

    FY26

    -50M
    -40M
    -30M
    -20M
    -10M
    0
    0.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    35.00
    58.00 Average
    39.70 Current
    80.00 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell

    Latest Rating

    Date 10/9/2026
    Analyst Canaccord Genuity
    Rating Action Initiated
    Rating Buy
    Price Action Announces
    Price Target 65
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      0.00%

    • Return on Assets (ttm)

      -29.98%

    • Return on Equity (ttm)

      -50.00%

    • Revenue (ttm)

      --

    • Net Income Avi to Common (ttm)

      -85.69M

    • Diluted EPS (ttm)

      0.10

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      327.79M

    • Total Debt/Equity (mrq)

      1.57%

    • Levered Free Cash Flow (ttm)

      -53.92M

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    MPLT MapLight Therapeutics, Inc.
    7.58 -1.81%
    MAZE Maze Therapeutics, Inc.
    31.48 -1.41%
    EVMN Evommune, Inc.
    6.73 -1.17%
    MBX MBX Biosciences, Inc.
    55.87 +2.44%
    RAPP Rapport Therapeutics, Inc.
    25.05 +3.47%
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: